vs

Side-by-side financial comparison of NLIGHT, INC. (LASR) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

PROCEPT BioRobotics Corp is the larger business by last-quarter revenue ($83.1M vs $81.2M, roughly 1.0× NLIGHT, INC.). NLIGHT, INC. runs the higher net margin — -6.0% vs -38.1%, a 32.0% gap on every dollar of revenue. On growth, NLIGHT, INC. posted the faster year-over-year revenue change (71.3% vs 20.2%). Over the past eight quarters, NLIGHT, INC.'s revenue compounded faster (35.0% CAGR vs 24.8%).

nLight Inc. is a global developer and manufacturer of high-performance semiconductor lasers, fiber lasers, and related optical components. Its products serve key segments including industrial precision manufacturing, aerospace and defense, medical equipment, and advanced research, with customers across North America, Europe, and Asia Pacific.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

LASR vs PRCT — Head-to-Head

Bigger by revenue
PRCT
PRCT
1.0× larger
PRCT
$83.1M
$81.2M
LASR
Growing faster (revenue YoY)
LASR
LASR
+51.1% gap
LASR
71.3%
20.2%
PRCT
Higher net margin
LASR
LASR
32.0% more per $
LASR
-6.0%
-38.1%
PRCT
Faster 2-yr revenue CAGR
LASR
LASR
Annualised
LASR
35.0%
24.8%
PRCT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
LASR
LASR
PRCT
PRCT
Revenue
$81.2M
$83.1M
Net Profit
$-4.9M
$-31.6M
Gross Margin
30.7%
64.9%
Operating Margin
-6.7%
-4.1%
Net Margin
-6.0%
-38.1%
Revenue YoY
71.3%
20.2%
Net Profit YoY
80.3%
-27.9%
EPS (diluted)
$-0.10
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LASR
LASR
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$81.2M
$76.4M
Q3 25
$66.7M
$83.3M
Q2 25
$61.7M
$79.2M
Q1 25
$51.7M
$69.2M
Q4 24
$47.4M
$68.2M
Q3 24
$56.1M
$58.4M
Q2 24
$50.5M
$53.4M
Net Profit
LASR
LASR
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$-4.9M
$-29.8M
Q3 25
$-6.9M
$-21.4M
Q2 25
$-3.6M
$-19.6M
Q1 25
$-8.1M
$-24.7M
Q4 24
$-25.0M
$-18.9M
Q3 24
$-10.3M
$-21.0M
Q2 24
$-11.7M
$-25.6M
Gross Margin
LASR
LASR
PRCT
PRCT
Q1 26
64.9%
Q4 25
30.7%
60.6%
Q3 25
31.1%
64.8%
Q2 25
29.9%
65.4%
Q1 25
26.7%
63.9%
Q4 24
2.4%
64.0%
Q3 24
22.4%
63.2%
Q2 24
23.5%
59.0%
Operating Margin
LASR
LASR
PRCT
PRCT
Q1 26
-4.1%
Q4 25
-6.7%
-40.6%
Q3 25
-10.9%
-27.8%
Q2 25
-6.9%
-28.0%
Q1 25
-18.6%
-39.7%
Q4 24
-55.8%
-28.9%
Q3 24
-21.0%
-38.4%
Q2 24
-25.1%
-50.3%
Net Margin
LASR
LASR
PRCT
PRCT
Q1 26
-38.1%
Q4 25
-6.0%
-39.1%
Q3 25
-10.3%
-25.7%
Q2 25
-5.8%
-24.7%
Q1 25
-15.7%
-35.8%
Q4 24
-52.7%
-27.6%
Q3 24
-18.4%
-35.9%
Q2 24
-23.2%
-48.0%
EPS (diluted)
LASR
LASR
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$-0.10
$-0.54
Q3 25
$-0.14
$-0.38
Q2 25
$-0.07
$-0.35
Q1 25
$-0.16
$-0.45
Q4 24
$-0.52
$-0.34
Q3 24
$-0.21
$-0.40
Q2 24
$-0.25
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LASR
LASR
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$98.7M
$245.6M
Total DebtLower is stronger
$51.7M
Stockholders' EquityBook value
$226.7M
$347.7M
Total Assets
$315.2M
$487.1M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LASR
LASR
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$98.7M
$286.5M
Q3 25
$81.1M
$294.3M
Q2 25
$78.8M
$302.7M
Q1 25
$82.2M
$316.2M
Q4 24
$65.8M
$333.7M
Q3 24
$41.5M
$196.8M
Q2 24
$49.4M
$214.1M
Total Debt
LASR
LASR
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
LASR
LASR
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$226.7M
$365.9M
Q3 25
$218.5M
$380.3M
Q2 25
$216.0M
$385.8M
Q1 25
$212.8M
$389.2M
Q4 24
$216.4M
$402.2M
Q3 24
$235.3M
$241.2M
Q2 24
$239.5M
$251.8M
Total Assets
LASR
LASR
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$315.2M
$508.1M
Q3 25
$298.7M
$511.5M
Q2 25
$295.3M
$513.1M
Q1 25
$290.0M
$519.4M
Q4 24
$270.2M
$534.0M
Q3 24
$291.3M
$374.1M
Q2 24
$294.3M
$374.4M
Debt / Equity
LASR
LASR
PRCT
PRCT
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LASR
LASR
PRCT
PRCT
Operating Cash FlowLast quarter
$17.5M
Free Cash FlowOCF − Capex
$15.9M
FCF MarginFCF / Revenue
19.6%
Capex IntensityCapex / Revenue
2.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$12.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LASR
LASR
PRCT
PRCT
Q1 26
Q4 25
$17.5M
$-10.3M
Q3 25
$5.2M
$-6.6M
Q2 25
$-1.4M
$-15.0M
Q1 25
$-20.0K
$-17.0M
Q4 24
$-3.9M
$-32.4M
Q3 24
$-5.6M
$-18.8M
Q2 24
$-4.2M
$-15.7M
Free Cash Flow
LASR
LASR
PRCT
PRCT
Q1 26
Q4 25
$15.9M
$-12.2M
Q3 25
$2.4M
$-9.5M
Q2 25
$-3.8M
$-17.8M
Q1 25
$-2.3M
$-18.8M
Q4 24
$-6.5M
$-33.6M
Q3 24
$-7.2M
$-19.0M
Q2 24
$-6.4M
$-16.8M
FCF Margin
LASR
LASR
PRCT
PRCT
Q1 26
Q4 25
19.6%
-15.9%
Q3 25
3.7%
-11.4%
Q2 25
-6.1%
-22.5%
Q1 25
-4.5%
-27.2%
Q4 24
-13.7%
-49.2%
Q3 24
-12.9%
-32.6%
Q2 24
-12.6%
-31.4%
Capex Intensity
LASR
LASR
PRCT
PRCT
Q1 26
Q4 25
2.0%
2.4%
Q3 25
4.2%
3.4%
Q2 25
3.9%
3.5%
Q1 25
4.4%
2.7%
Q4 24
5.5%
1.7%
Q3 24
2.9%
0.4%
Q2 24
4.2%
2.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LASR
LASR

Aerospaceand Defense$56.3M69%
Microfabrication$14.2M18%
Industrial$10.7M13%

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons